StockData
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. (SNOA) stock

SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3078% below fair value
$1.09−0.08 (-6.84%)

Close on Nov 13, 2026Market cap $5.22MP/E –Yield –

Sonoma Pharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Sonoma Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -3.3%. For fiscal 2026 it was -12.6%, against -26.0% the year before. The highest annual figure on record is -12.6% in fiscal 2026.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2026Mar 31, 2026-12.6%+13.4
FY2025Mar 31, 2025-26.0%+10.9
FY2024Mar 31, 2024-36.9%−2.5
FY2023Mar 31, 2023-34.4%+12.2
FY2022Mar 31, 2022-46.6%−28.1
FY2021Mar 31, 2021-18.5%+22.7
FY2020Mar 31, 2020-41.2%+18.1
FY2019Mar 31, 2019-59.3%+25.8
FY2018Mar 31, 2018-85.2%+16.0
FY2017Mar 31, 2017-101.2%+55.9
FY2016Mar 31, 2016-157.0%−109.0
FY2015Mar 31, 2015-48.1%−3.8
FY2014Mar 31, 2014-44.3%−22.4
FY2013Mar 31, 2013-21.8%+28.9
FY2012Mar 31, 2012-50.7%+26.2
FY2011Mar 31, 2011-76.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2027CQ3 2026Sep 30, 20264.0%+10.1
Q1 FY2027CQ2 2026Jun 30, 2026-0.6%+26.6
Q4 FY2026CQ1 2026Mar 31, 2026-6.3%+11.2
Q3 FY2026CQ4 2025Dec 31, 2025-15.6%+13.3
Q2 FY2026CQ3 2025Sep 30, 2025-6.0%+17.7
Q1 FY2026CQ2 2025Jun 30, 2025-27.3%+7.3
Q4 FY2025CQ1 2025Mar 31, 2025-17.5%+23.5
Q3 FY2025CQ4 2024Dec 31, 2024-28.9%−2.0
Q2 FY2025CQ3 2024Sep 30, 2024-23.7%+20.5
Q1 FY2025CQ2 2024Jun 30, 2024-34.6%+1.6
Q4 FY2024CQ1 2024Mar 31, 2024-41.0%−2.9
Q3 FY2024CQ4 2023Dec 31, 2023-26.9%+35.4
Q2 FY2024CQ3 2023Sep 30, 2023-44.2%−22.3
Q1 FY2024CQ2 2023Jun 30, 2023-36.2%−14.7
Q4 FY2023CQ1 2023Mar 31, 2023-38.1%+95.1
Q3 FY2023CQ4 2022Dec 31, 2022-62.3%−29.3
Q2 FY2023CQ3 2022Sep 30, 2022-21.9%+3.8
Q1 FY2023CQ2 2022Jun 30, 2022-21.5%+3.1
Q4 FY2022CQ1 2022Mar 31, 2022-133.2%−2.7
Q3 FY2022CQ4 2021Dec 31, 2021-33.0%−30.2
Q2 FY2022CQ3 2021Sep 30, 2021-25.7%−28.7
Q1 FY2022CQ2 2021Jun 30, 2021-24.5%−13.0
Q4 FY2021CQ1 2021Mar 31, 2021-130.5%−55.7
Q3 FY2021CQ4 2020Dec 31, 2020-2.8%+22.4
Q2 FY2021CQ3 2020Sep 30, 20202.9%+30.2
Q1 FY2021CQ2 2020Jun 30, 2020-11.5%+27.9
Q4 FY2020CQ1 2020Mar 31, 2020-74.8%−13.1
Q3 FY2020CQ4 2019Dec 31, 2019-25.2%+19.3
Q2 FY2020CQ3 2019Sep 30, 2019-27.2%+26.5
Q1 FY2020CQ2 2019Jun 30, 2019-39.4%+41.9
Q4 FY2019CQ1 2019Mar 31, 2019-61.7%+68.2
Q3 FY2019CQ4 2018Dec 31, 2018-44.5%+21.6
Q2 FY2019CQ3 2018Sep 30, 2018-53.7%+12.4
Q1 FY2019CQ2 2018Jun 30, 2018-81.3%+6.9
Q4 FY2018CQ1 2018Mar 31, 2018-129.9%−57.7
Q3 FY2018CQ4 2017Dec 31, 2017-66.1%+40.0
Q2 FY2018CQ3 2017Sep 30, 2017-66.1%–
Q1 FY2018CQ2 2017Jun 30, 2017-88.2%–
Q4 FY2017CQ1 2017Mar 31, 2017-72.3%–
Q3 FY2017CQ4 2016Dec 31, 2016-106.1%–

More Sonoma Pharmaceuticals figures

See a number that looks wrong?